Eton Pharmaceuticals (ETON) Projected to Post Quarterly Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.53 million for the quarter.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $15.58 on Friday. The business has a 50 day simple moving average of $15.33 and a 200-day simple moving average of $11.23. The stock has a market capitalization of $405.87 million, a PE ratio of -70.82 and a beta of 1.37. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $18.41.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ETON shares. Craig Hallum increased their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. B. Riley started coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, HC Wainwright increased their price objective on Eton Pharmaceuticals from $17.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.